Account

We’ll launch your pharmaceuticals to new heights

Specialist and experienced pricing and market access consultancy

Insider Insights

Worldwide: New Coalition to improve access to canc…

According to the UICC, “priority will be given to medicines currently on the WHO Essential Medicin…
Read more
Insider Insights

World’s first CRISPR medicine approved in UK for…

The MHRA grants conditional approval to Casgevy, the first-ever CRISPR gene-editing therapy for sick…
Read more
Insider Insights

World’s first CRISPR-based Gene Therapy Exa-cel …

NICE recommends gene therapy for severe beta-thalassaemia, offering hope for improved quality of lif…
Read more
161 Pharma & biotech companies worked with
11 We work with 11 of the top 20 pharma companies
95% Positive feedback from our training courses
57 We’ve supported pricing and access strategies in 57 countries worldwide

Our Services

From launching your product to access training

Launch Implementation

We will develop and implement a successful launch strategy for your product.

Find out more

Price Optimization

We build payer focussed pricing and market access strategies to enable commercial success.

Find out more

Market Access Training

We provide engaging training solutions that ensures your organisation stays ahead of the ever-changing market access landscape.

Find out more

Our mission

To enable patient access to your products

Unifying our internal strengths and external partnerships helps solve your pricing and market access challenges to drive patient access of your pharmaceutical products.

Our strategy

We have the expertise to get your products into doctors hands

Clearly and concisely communicate key scientific, economic and commercial messages to enable company employees to effectively communicate the product’s value.

How we work

Bespoke approach

Individual solutions to suit you

Flexible

We adapt our working style to reflect your needs

Real-world pharma experience

We have a wealth of practical knowledge & experience within the pharma industry & HTA bodies

Responsive

We react quickly and effectively to provide the best support possible

Updates & News

Latest research and publications

Articles
17.09.2025
Why Gene Therapies Keep Hitting Price & Access…

The pricing benchmark has shifted faster than systems have adapted. In the UK, prices for one-time t…

Read more
Guide
08.09.2025
The BRAVE Approach: Your Guide to Early Payer Scie…

Successfully navigating early payer scientific advice whether through Joint Scientific Consultations…

Read more
Guide
08.09.2025
NICE Summary Guide 2025: What the Appraisal Reform…

NICE has introduced important appraisal reforms for 2025 that will directly impact manufacturers pre…

Read more
Checklist
08.09.2025
NICE Submission Checklist: Your Guide to STA &…

Preparing a NICE submission can feel overwhelming. Whether it’s a Single Technology Appraisal (STA…

Read more
Articles
08.09.2025
Innovative Payment Models: Outcomes‑Based, Annui…

In 2010, the world’s most expensive therapy was Soliris (eculizumab), costing around USD 409,500 p…

Read more
Articles
08.09.2025
The JCA is here – are you generating the right e…

Five success pillars — your JCA evidence-generation checklist  From 12th January 2025, the Eu…

Read more
Articles
08.09.2025
ATMP pricing landscape: why traditional models bre…

A €3 million invoice for a single infusion can dazzle as easily as it alarms. Gene therapies such …

Read more
Articles
03.09.2025
Proving LongTerm Value: Evidence Strategies Payers…

Proving the long-term value of pharmaceutical assets remains one of the biggest challenges for manuf…

Read more
News
01.09.2025
US Biotech, what is the latest on Trump’s two …

To date, there are two different levers in play under Trump’s “Most Favored Nation”, 1. A drug…

Read more
Visit our resource library

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.